Dasiglucagon: First Approval

Link to article at PubMed

Drugs. 2021 May 28. doi: 10.1007/s40265-021-01531-z. Online ahead of print.

ABSTRACT

Dasiglucagon (Zegalogue®) is an antihypoglycaemic agent being developed by Zealand Pharma for the treatment of hypoglycaemia, type 1 diabetes mellitus (T1DM) management and congenital hyperinsulinism. In March 2021, dasiglucagon received its first approval in the USA for the treatment of severe hypoglycaemia in paediatric and adult patients with diabetes aged 6 years and above. Dasiglucagon, a glucagon analogue, is available as a single-dose autoinjector or prefilled syringe for subcutaneous injection. This article summarizes the milestones in the development of dasiglucagon leading to this first approval for hypoglycaemia.

PMID:34047955 | DOI:10.1007/s40265-021-01531-z

Leave a Reply

Your email address will not be published.